Cortagen (Ala-Glu-Asp-Pro): Cortexin-Derived Tetrapeptide, Preclinical Nerve-Regeneration Signals, and Gene-Expression Hypotheses in Neural Research
Abstract Cortagen is a synthetic tetrapeptide with the sequence AlaGluAspPro (AEDP). It was developed by directed synthesis after aminoacid analysis of Cortexin, a heterogeneous braincortex peptide preparation, and should not be treated as interchangeable with the parent extract. The direct Cortagen literature is small and predominantly preclinical. Accessible studies include a rat sciaticnerve transectionandsuture model, a mouseheart transcriptomics experiment, rodent chroniccerebralischemia research, and mouse behavioral work [1–4]. The experimental findings justify cautious investigation of shortpeptide biology, not therapeutic conclusions. A sciaticnerve study reported increased regenerationrate and conductionvelocity endpoints in rats [1]. A fiveday mouse study found altered cardiac expression among a subset of measured transcripts after Cortagen exposure [2]. Other reports describe behavior, redox, or ischemiaassociated outcomes in rodents [3,4]. No peerreviewed, wellcontrolled human efficacy, pharmacokinetic, doseranging, biodistribution, or longterm safety program specific to Cortagen was identified in the reviewed sources. This article therefore presents Cortagen as an investigational research compound and separates its evidence from broader claims made for Cortexin or the Khavinson shortpeptide framework. 1. Molecular Identity and Research Lineage 1.1 Sequence, Formula, and Physicochemical Character Cortagen is the linear tetrapeptide HAlaGluAspProOH, commonly abbreviated AEDP. PubChem lists the compound as CID 18439621, with formula C₁₇H₂₆N₄O₉, molecular weight 430.4 g/mol, and CAS number 335591032 [5]. Alanine contributes a small Nterminal methyl side chain; glutamate and aspartate contribute two acidic carboxyl side chains; and proline creates a fivemembered pyrrolidine ring that constrains the Cterminal backbone. The compact, polar structure is consistent with an ultrashortpeptide research tool, but molecular size alone does not establish cellular uptake, brain exposure, or pharmacologic selectivity in vivo. 1.2 Cortexin Relationship: A Required Distinction Cortagen was designed from fractionlevel aminoacid analysis of Cortexin rather than isolated as a single endogenous Cortagen molecule. Cortexin is a complex polypeptide preparation; Cortagen is a defined synthetic tetrapeptide [2,4]. This distinction is critical when evaluating the literature. Evidence from an extract may reflect a mixture of molecular components, batch characteristics, or interactions that AEDP cannot reproduce. Conversely, a finding with AEDP does not validate all claims associated with Cortexin. In this article, the two compounds are discussed together only when a cited study directly compared them. 2. ShortPeptide Bioregulation: Proposed Mechanisms 2.1 The DNA/HistoneInteraction Hypothesis A body of work associated with the Khavinson shortpeptide program proposes that peptides containing two to seven amino acids may enter cells and nuclei, interact with DNA or histones, and influence transcriptional accessibility or gene expression [6,7]. This literature provides a hypothesis for how ultrashort peptides could produce tissuelevel phenotypes without a conventional membrane receptor being identified. However, these mechanisms are not resolved Cortagen pharmacology. The currently accessible sources do not establish a unique Cortagen receptor, a direct AEDPbinding site in living brain tissue, or a causal chain from AEDP exposure to a specific neural transcriptome and functional endpoint. 2.2 From Expression Association to Mechanistic Proof Transcriptomic association must be differentiated from causal genomic targeting. In the 2004 heartmicroarray study, Cortagen exposure was associated with altered expression among 234 clones corresponding to 110 known genes on the investigators’ platform [2]. That finding supports the feasibility of further mechanism studies, but it does not prove direct binding to DNA, predict which genes would change in the brain, or show that transcript changes caused functional benefit. Stronger mechanistic evidence would require direct uptake measurements, targetengagement assays, orthogonal transcriptomics, chromatinaccessibility experiments, peptide–protein interactomics, and independent replication in neural cell systems. “The synthetic tetrapeptide Cortagen (AlaGluAspPro) was obtained by directed synthesis based on amino acid analysis of natural brain cortex peptide preparation Cortexin.” — Anisimov et al., Neuro Endocrinology Letters, 2004 [2] 3. Direct Preclinical Cortagen Evidence 3.1 SciaticNerve Regeneration Model Turchaninova and colleagues evaluated Cortagen in a rat model involving sciaticnerve transsection and surgical repair. The abstract reports that Cortagen administration during the postsurgical period was associated with a 27% increase in regeneratingfiber growth rate and a 40% increase in conduction velocity [1]. These findings provide a direct peripheralnerveregeneration signal in o
For research use only. Not for human consumption.